Lab

Chiung Chi Peng's Lab

Featured research (2)

Dysregulation of fatty acid oxidation and accumulation of fatty acids can cause kidney injury. Nifedipine modulates lipogenesis-related transcriptional factor SREBP-1/2 in proximal tubular cells by inhibiting the Adenosine 5‘-monophosphate (AMP)-activated protein kinase (AMPK) pathway in vitro. However, the mechanisms by which nifedipine (NF) modulates lipotoxicity in vivo are unclear. Here, we examined the effect of NF in a doxorubicin (DR)-induced kidney injury rat model. Twenty-four Sprague–Dawley rats were divided into control, DR, DR+NF, and high-fat diet (HFD) groups. The DR, DR+NF, and HFD groups showed hypertension and proteinuria. Western blotting and immunohistochemical analysis showed that NF significantly induced TNF-α, CD36, SREBP-1/2, and acetyl-CoA carboxylase expression and renal fibrosis, and reduced fatty acid synthase and AMPK compared to other groups (p < 0.05). Additionally, 18 patients with chronic kidney disease (CKD) who received renal transplants were enrolled to examine their graft fibrosis and lipid contents via transient elastography. Low-density lipoprotein levels in patients with CKD strongly correlated with lipid contents and fibrosis in grafted kidneys (p < 0.05). Thus, NF may initiate lipogenesis through the SREBP-1/2/AMPK pathway and lipid uptake by CD36 upregulation and aggravate renal fibrosis in vivo. Higher low-density lipoprotein levels may correlate with renal fibrosis and lipid accumulation in grafted kidneys of patients with CKD.
Background: Pulmonary embolism (PE) is frequently associated with cancer. This study aimed to assess patients with acute PE and identify diagnostic predictors of new cancer after 1 year of follow-up. Methods: One hundred and twenty-one patients with PE were enrolled consecutively from the emergency department of a single medical center in Taiwan. Data from computed tomography angiography, echocardiogram, electrocardiogram and for baseline comorbidities, clinical presentation, and laboratory parameters were recorded. The surviving discharged patients without a cancer diagnosis were followed-up for 1 year, and new malignancies were recorded. Results: Of 121 patients with acute PE, 44 (36 %) had an underlying cancer history (cancer group), and 77 (64 %) did not (non-cancer group). Baseline demographic characteristics, comorbidities, clinical symptoms, biochemical parameters, echocardiogram data, and electrocardiogram data of the two groups were similar except for a higher hospital mortality rate (56.8 % vs. 9.1 %, P<0.001), lower body mass index (22.6±4.1 vs. 25.5±4.9, P=0.02), higher systolic blood pressure (139.7±33.7 vs. 125.4±24.1, P=0.02), lower low-density lipoprotein level (67.4±38.3 vs. 90.4±33.8, P=0.04), lower creatinine kinase (CK) (43.0±43.0 vs. 83.5±83.1, P=0.01), higher myocardial band (MB) form of CK ratio (0.2±0.2 vs. 0.1±0.1, P<0.01), higher partial pressure of arterial oxygen (122.81±81.2 vs. 90.2±59.4, P=0.03), and less presentation of chest pain (15.9 % vs. 40.3 %, P=0.01) in the cancer group. Kaplan-Meier curve analysis revealed that the 30-day survival rate was higher in the non-cancer group than in the cancer group (log-rank P=0.04). After 1 year of follow-up, 6 of 59 (10.17 %) initial non-cancer-related PE survivors were diagnosed with malignancies. After multivariate analysis, only the initial CK-MB level was associated with a diagnosis of new cancer (hazard ratio (HR): 1.37, 95 % confidence interval (CI) [1.029–1.811], P=0.03). Conclusions: This study suggests that the CK-MB level is associated with future malignancy in patients with PE. Patients with cancer-related PE had a worse 30-day survival rate. Keywords: Cancer; Creatinine kinase; Deep vein thrombosis; Pulmonary embolism; Mortality

Lab head

Chiung Chi Peng
Department
  • Graduate Institute of Clinical Medicine

Members (7)

Mai-Szu Wu
  • Chang Gung Memorial Hospital
Kuan-Chou Chen
  • Taipei Medical University
Yen Chung Lin
  • Taipei Medical University Hospital
Su Chan Chen
  • Taipei Veterans General Hospital
Chi-Ming Huang
Chi-Ming Huang
  • Not confirmed yet
Chang-Yu Chen
Chang-Yu Chen
  • Not confirmed yet